Treatment of rheumatoid arthritis by TNF-blocking agents

International Archives of Allergy and Immunology

Volumn 127, Issue 1, 2002, Pages 10-14

  Graninger, Winfried ^a,b   Smolen, Josef ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cytokine blockade; Disease modifying drug; Etanercept; Infliximab; Monoclonal antibody; Rheumatoid arthritis; Treatment; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; AFELIMOMAB; CERTOLIZUMAB PEGOL; CYTOKINE ANTIBODY; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; CHIMERA; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOGLOBULIN G; MICE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036121085     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048164     Document Type: Review

References (62)

1. Adult and juvenile rheumatoid arthritis: Current epidemiologic concepts
2. What is the natural history of rheumatoid arthritis?
3. Disability in rheumatoid arthritis: Comparison of prognostic factors across three populations
4. Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts
5. Pannocytes: Distinctive cells found in rheumatoid arthritis articular cartilage erosions
6. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: A possible role of CD69
7. IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells
8. Pathogenesis of rheumatoid arthritis: Cellular and cytokine interactions
9. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases
10. Detection of activated T cell products in the rheumatoid joint using cDNA probes to interleukin-2 (IL-2) IL-2 receptor and IFN-gamma
11. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
12. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
13. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo
14. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
15. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF
16. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease
17. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis
18. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis
19. Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells
20. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis
21. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy
22. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
23. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
24. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
25. Infliximab and methotrexate in the treatment of rheumatoid arthritis
26. Anti-cytokine therapy for rheumatoid arthritis
27. CDP870, a novel, pegylated, humanized TNF-alpha inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis
28. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyper-inflammatory response during severe sepsis: The RAMSES study
29. The ARMADA trial: A double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7) in patients with active RA on methotrexate
30. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
31. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
32. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis
33. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
34. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
35. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway
36. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials
37. Drug-induced lupus
38. Safety of infliximab in clinical trials
39. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
40. Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis
41. Long term safety of infliximab
42. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
43. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group
44. Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept
45. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
46. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group
47. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate
48. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis
49. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis
50. One-year inhibition of tumor necrosis factor-alpha: A major success or a larger puzzle?
51. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody
52. A double-blind, randomised, placebo-controlled trial of anti-interleukin-6 (IL-6) receptor monoclonal antibody in rheumatoid arthritis
53. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores
54. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
55. Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis
56. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: A pilot study
57. Etanercept in juvenile rheumatoid arthritis
58. Etanercept in children with polyarticular juvenile rheumatoid arthritis
59. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
60. New treatment options in spondyloarthropathies: Increasing evidence for significant efficacy of anti-tumor necrosis factor therapy
61. New concepts in treatment protocols for severe systemic vasculitis
62. Successful treatment of refractory Wegener's granulomatosis with infliximab